Journal
ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
Volume 46, Issue -, Pages 1046-1052Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/21691401.2018.1478423
Keywords
Nanotechnology; drug delivery systems; nanostructures; cardiotoxicity; biodistribution
Categories
Funding
- Fundacao de Apoio a Pesquisa do Distrito Federal (FAP/DF) [0193.001020/2015]
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [447628/2014-3]
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
Ask authors/readers for more resources
Nanocapsules containing selol and doxorubicin (NCS-DOX) with an oily core of selol and a shell of poly(methyl vinyl ether-co-maleic anhydride) covalently conjugated to doxorubicin were developed in a previous work. In this study, these nanocapsules showed a similar antitumour effect in comparison to the free doxorubicin (DOX) treatment, but showed no evident DOX-related cardiotoxicity, as evidenced by serum creatine kinase-MB (CK-MB) activity. The histopathological analysis showed that the free DOX treatment induced more intense morphological damage to myocardial tissues in comparison to NCS-DOX treatment. Animals treated with free DOX presented important muscle fibre degradation and animals treated with NCS-DOX, heart tissue did not present signals of muscle fibre degeneration. These results indicate that the cardiotoxicity related to DOX is reduced when this drug is carried by the NCS-DOX. Noteworthy, biodistribution analyses showed that NCS-DOX accumulated more intensely in tumours than the free DOX. Thus, this study reinforces the importance of the development of nanocapsules as drug carriers for the treatment of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available